Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases, eliminating the need for preconditioning chemotherapy. Lead candidate Descartes-08 showed promising ...
Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a note issued to investors on Wednesday,Benzinga reports. They ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback